Efficacy of lanadelumab at fixed and modified dosing regimens in patients aged 2 to <12 years old with hereditary angioedema (HAE) in the phase 3, open-label, multicenter SPRING Study
Authors:
- William LumryWLWilliam Lumry
- Jonathan BernsteinJBJonathan Bernstein
- Raffi TachdjianRTRaffi Tachdjian
- H. James WednerHWH. James Wedner
- William YangWYWilliam Yang
- Marcus MaurerMMMarcus Maurer
- Inmaculada Martinez-SaguerIMInmaculada Martinez-Saguer
- Henriette FarkasHFHenriette Farkas
- Christina NurseCNChristina Nurse
- Ming YuMYMing Yu
- 3 February 2023
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 151 (2) , AB140